In the Claims:

Please amend claims 7, 10, 12-14 and 16, without prejudice or disclaimer, as follows:

Claims 1-6 (Canceled).

7. (Currently amended) ~~A CS 193~~ An isolated polypeptide having at least ~~60%~~ 85% identity with an amino acid sequence selected from the group consisting of ~~SEQUENCE ID NOS~~ SEQ ID NOS: 41-49, and fragments thereof.

8. (Currently amended) The isolated polypeptide of claim 7, wherein said polypeptide is produced by recombinant techniques.

9. (Currently amended) The isolated polypeptide of claim 7, wherein said polypeptide is produced by synthetic techniques.

10. (Currently amended) An antibody which specifically binds to ~~at least one CS 193 epitope~~ a polypeptide, wherein said ~~CS193 epitope~~ polypeptide ~~is derived from an amino acid sequence having~~ has at least ~~50%~~ 85% identity to an amino acid sequence selected from the group consisting of ~~SEQUENCE ID NOS~~ SEQ ID NOS: 41-49, and fragments thereof.

Claim 11 (Canceled).

12. (Currently amended) A method for producing a polypeptide, ~~comprising at least one CS193 epitope,~~ said method comprising incubating host cells that have been transfected with an expression vector containing a polynucleotide sequence encoding a polypeptide, wherein said polypeptide comprises an amino acid sequence having at least ~~60%~~ 85% identity with an amino acid sequence selected from the group consisting of ~~SEQUENCE ID NOS~~ SEQ ID NOS: 41-49, and fragments thereof.

13. (Currently amended) A method for producing antibodies which specifically bind to ~~CS193~~ an antigen, said method comprising administering to an individual an isolated immunogenic polypeptide or fragment thereof in an amount sufficient to elicit an immune response, wherein said immunogenic polypeptide ~~comprises at least one CS193 epitope and~~ has at least ~~50%~~ 85% identity with a sequence selected from the group consisting of ~~SEQUENCE ID NOS~~ SEQ ID NOS: 41-49, and fragments thereof.

14. (Currently amended) A method for producing antibodies which specifically bind to ~~CS193~~ an antigen, said method comprising administering to an individual a plasmid comprising a polynucleotide sequence which encodes ~~at least one CS193 epitope derived from~~ a ~~polynucleotide~~ polypeptide having an amino acid sequence selected from the group consisting of ~~SEQUENCE ID NOS~~ SEQ ID NOS: 41-49, and fragments thereof.

Claim 15 (Canceled).

16. (Currently amended) A composition of matter comprising an isolated polypeptide ~~containing at least one CS193 epitope, wherein said polypeptide has~~ having at least ~~60%~~ 85% identity with a sequence selected from the group consisting of ~~SEQUENCE ID NOS~~ SEQ ID NOS: 41-49, and fragments thereof.

Claims 17-18 (Canceled).